The American Chemical Society (ACS) sponsors a bi-annual national conference for chemists to introduce new ideas, communicate results, network, and build professional skills. This fall, the 240th ACS meeting is being held August 22nd – 26th in Boston, MA, and the theme is “Chemistry for Combating and Preventing Disease.”
Olefin metathesis can play an important and growing role not only in producing important pharmaceutical ingredients (which can combat and prevent disease), but a number of other products as well. All Things Metathesis’s own Andy Nickel will fill in for Prof. Robert Grubbs and give a talk entitled, “New Businesses Based on the RCM Reaction” in the division of small chemical businesses (SCHB). It should be an interesting half hour for anyone interested in learning more about how Grubbs catalysts are used in the pharmaceutical, chemical, and polymer industries.
There are some other talks in the metathesis field that I’m looking forward to attending. Nobel Laureate Prof. Richard Schrock has developed a “third” generation of molybdenum and tungsten catalysts that utilize a monoalkoxide-pyrrolide (MAP) ligand combination resulting in improved catalytic activity and stereoselectivity. The talk entitled “Third generation: Thousands of new catalysts for olefin metathesis” will hopefully introduce just that—and in only 30 minutes. Wow!
With ruthenium, new catalyst development using isocyanate and isothiocyanate ligands in place of chlorides…
…and UV-triggered ROMP will be presented from Prof. Michael Buchmeiser’s group.
If you are going to the meeting, please stop by and see us at the Materia Booth (#1326) in the Exposition.
{ 0 comments } | 
Print This Post
|